Noninvasive markers for staging fibrosis in chronic delta hepatitis
Open Access
- 4 November 2016
- journal article
- research article
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 45 (1) , 127-138
Abstract
Summary: Background: Serum fibrosis markers are useful in staging chronic hepatitis B (HBV) and C (HCV) virus but have not been evaluated in chronic hepatitis D virus (HDV).Aim: To evaluate the utility of serum fibrosis markers [fibrosis‐4 score (FIB‐4), aspartate aminotransferase (AST) to alanine aminotransferase (ALT) ratio, aspartate aminotransferase ratio (AAR), age‐platelet index (API), AST‐to‐platelet‐ratio‐index (APRI) and Hui score] in HDV infection.Methods: Clinical and histologic laboratory data from HBV, HCV and HDV patients were evaluated and serum fibrosis markers were calculated. The ability of fibrosis markers to detect advanced fibrosis (Ishak ≥4) and cirrhosis (Ishak = 6) were evaluated and compared between viral infections.Results: A total of 1003 subjects (HCV = 701, HBV = 240 and HDV = 62) with mean age of 46 ± 11 and 66% male were evaluated. HDV subjects had higher ALT and AST than HCV and lower platelets than both HBV and HCV. Histologically, HDV had the greatest percentage of Ishak ≥4 and necroinflammation. FIB‐4 performed best in detecting advanced fibrosis and cirrhosis in all viral cohorts. In HDV, area under the receiver operator curve (AUROC) 95% confidence intervals for detecting advanced fibrosis were: FIB‐4 = 0.70 (0.55–0.84), API = 0.69 (0.55–0.82), APRI = 0.68 (0.54–0.82), Hui score = 0.63 (0.49–0.78), AAR = 0.63 (0.48–0.77). The AUROC for detecting cirrhosis in HDV were: FIB‐4 = 0.83 (0.69–0.97), API = 0.80 (0.66–0.95), APRI = 0.75 (0.61–0.89), Hui score = 0.70 (0.49–0.91) and AAR = 0.70 (0.48–0.93). Adjustment of published cut‐offs led to marginal improvements in FIB4 for advanced fibrosis and of APRI for cirrhosis in HDV.Conclusions: Serum fibrosis markers have lower performance accuracy in chronic HDV infected patients compared to HBV and HCV patients. Other noninvasive fibrosis markers should be explored to assist in the management of these patients.Keywords
Funding Information
- National Institute of Diabetes and Digestive and Kidney Diseases
This publication has 55 references indexed in Scilit:
- Coinfection with hepatitis B and D: Epidemiology, prevalence and disease in patients in Northern CaliforniaJournal of Gastroenterology and Hepatology, 2013
- Epidemiology of Hepatitis DSeminars in Liver Disease, 2012
- Diagnostic accuracy of the aspartate aminotransferase-to-platelet ratio index for the prediction of hepatitis B-related fibrosis: a leading meta-analysisBMC Gastroenterology, 2012
- Performance of the Aspartate Aminotransferase-to-Platelet Ratio Index for the Staging of Hepatitis C-Related Fibrosis: An Updated Meta-Analysis §ΔHepatology, 2010
- FIB-4Hepatology, 2007
- Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfectionHepatology, 2006
- A Simple Noninvasive Index Can Predict Both Significant Fibrosis and Cirrhosis in Patients With Chronic Hepatitis CHepatology, 2003
- Survival and complications in a cohort of patients with anti-Delta positive liver disease presenting in a tertiary referral clinicJournal of Hepatology, 1995
- Histological grading and staging of chronic hepatitisJournal of Hepatology, 1995
- Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis†Hepatology, 1981